Loratadine-loaded Niosomal Transdermal Patch for Treating Allergic Issues: A Design Expert’s Associated Fabrication and Evaluation

Chettinad Health City Medical Journal Pub Date : 2023-09-30 DOI:10.24321/2278.2044.202354

Charan Sailaja

{"title":"Loratadine-loaded Niosomal Transdermal Patch for Treating Allergic Issues: A Design Expert’s Associated Fabrication and Evaluation","authors":"Charan Sailaja","doi":"10.24321/2278.2044.202354","DOIUrl":null,"url":null,"abstract":"Introduction: Loratadine (LRD) is a second-generation H1 histamineantagonist and is helpful in the treatment of allergies.Methods: The Box Behnken design (BBD) was used in this study tocreate nine LRD niosomes, which were then cast in solvent and put ontransdermal patches. The niosomes’ dimensions, shape, zeta potential,and degree of entrapment efficiency were then assessed. On the LRDentrapment, the niosomes’ cholesterol, Span-40, Span-60, and Span-80concentrations were measured. The patch system was filled with theoptimised niosomal formulations. Then, each patch was described using itsphysicochemical properties and results from in vitro permeation studies.Results: Patches containing niosomal vesicles, in contrast to controlpatches, demonstrated improved drug release. It was shown thatniosomal patches exhibited greater penetration than control patches.Niosomes’ surfactant serves as a permeation enhancer and enhancesLRD permeation from niosomes.Conclusion: The study concluded that the niosome-based transdermalpatches might effectively distribute LRD medications trans-dermallywhile minimising GIT adverse effects. How to cite this article:Sailaja C, Bhupalam PK. Loratadine-loadedNiosomal Transdermal Patch for Treating AllergicIssues: A Design Expert’s Associated Fabricationand Evaluation. Chettinad Health City Med J.2023;12(3):69-78. DOI: https://doi.org/10.24321/2278.2044.202354","PeriodicalId":276735,"journal":{"name":"Chettinad Health City Medical Journal","volume":"4 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chettinad Health City Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24321/2278.2044.202354","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Loratadine (LRD) is a second-generation H1 histamineantagonist and is helpful in the treatment of allergies.Methods: The Box Behnken design (BBD) was used in this study tocreate nine LRD niosomes, which were then cast in solvent and put ontransdermal patches. The niosomes’ dimensions, shape, zeta potential,and degree of entrapment efficiency were then assessed. On the LRDentrapment, the niosomes’ cholesterol, Span-40, Span-60, and Span-80concentrations were measured. The patch system was filled with theoptimised niosomal formulations. Then, each patch was described using itsphysicochemical properties and results from in vitro permeation studies.Results: Patches containing niosomal vesicles, in contrast to controlpatches, demonstrated improved drug release. It was shown thatniosomal patches exhibited greater penetration than control patches.Niosomes’ surfactant serves as a permeation enhancer and enhancesLRD permeation from niosomes.Conclusion: The study concluded that the niosome-based transdermalpatches might effectively distribute LRD medications trans-dermallywhile minimising GIT adverse effects. How to cite this article:Sailaja C, Bhupalam PK. Loratadine-loadedNiosomal Transdermal Patch for Treating AllergicIssues: A Design Expert’s Associated Fabricationand Evaluation. Chettinad Health City Med J.2023;12(3):69-78. DOI: https://doi.org/10.24321/2278.2044.202354

查看原文本刊更多论文

用于治疗过敏问题的氯雷他定负载Niosomal透皮贴剂:设计专家的相关制作和评估

简介:氯雷他定(LRD)是第二代H1组胺拮抗剂，有助于治疗过敏。方法:采用Box - Behnken设计(BBD)法制备9个LRD小体，经溶剂浇铸后贴于透皮贴剂上。然后评估纳米体的尺寸，形状，zeta电位和捕获效率程度。在LRDentrapment上，测定小体胆固醇、Span-40、Span-60和span -80浓度。贴片系统充满了优化的乳泌体配方。然后，使用其物理化学性质和体外渗透研究的结果来描述每个贴片。结果:与对照贴片相比，含有乳质体囊泡的贴片改善了药物释放。结果表明，乳质体贴片比对照贴片具有更大的穿透性。乳质体表面活性剂作为渗透促进剂，增强乳质体对lrd的渗透。结论:基于nioome的透皮贴剂可以有效地将LRD药物经皮分发，同时最大限度地减少GIT的不良反应。Sailaja C, Bhupalam PK。氯雷他定负载niosomal透皮贴剂治疗过敏问题:设计专家的相关制作和评估。中华卫生杂志;2009;12(3):69-78。DOI: https://doi.org/10.24321/2278.2044.202354

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chettinad Health City Medical Journal

自引率

0.00%

发文量